Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer.

After 3 years’ median follow-up, the PFS difference between atezolizumab and placebo did not reach statistical significance (median 13.5 vs 11.3 months, HR=0.83; 95% CI=0.69–0.99; p=0.041) or in PD-L1-positive (median 15.2 vs 13.1 months, HR=0.86; 95% CI=0.63–1.16; p=0.300) populations.

also in 45,344 other papers

Although the OS data were not mature at the time of the interim analysis, a positive trend in favor of pembrolizumab plus concurrent chemoradiotherapy was observed (HR=0.73; 95% CI=0.49–1.07).

also in 4,667 other papers

For all comers, it showed a trend towards improved OS.

also in 21,081 other papers